SkinHealth Systems Inc. SKIN
- Market cap
- $78.4M
- P/E
- 0.0×
Follow SKIN
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | 10.01 | 9.71 | 8.25 | 1.35 | 0.91 | 0.78 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | 12.84 | 30.17 | 24.77 | 13.90 | 5.17 | 2.69 |
High Price
|
|||
| — | — | — | — | 2 | 704 | 1,034 | 881 | 769 | 613 |
Employees
|
|||
| — | — | — | 0 | 60 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | 167 | 119 | 260 | 366 | 398 | 334 | 301 |
Revenue
|
|||
| — | — | — | 63.92% | 56.43% | 68.65% | 68.00% | 38.97% | 54.53% | 65.28% |
Gross Margin
|
|||
| — | — | — | (3) | (38) | (381) | 45 | (102) | (30) | (6) |
EBT
|
|||
| — | — | — | (1.76%) | (32.31%) | (146.35%) | 12.39% | (25.60%) | (8.84%) | (1.97%) |
EBT Margin
|
|||
| — | 0 | — | (2) | (29) | (379) | 44 | (100) | (29) | (10) |
Net Income
|
|||
| — | — | — | 15 | 16 | 22 | 27 | 39 | 37 | 29 |
Depreciation
|
|||
| — | — | — | 5.18 | 3.47 | 2.55 | 2.48 | 3.02 | 2.70 | 2.38 |
Revenue/Sh
|
|||
| — | — | — | (0.05) | (0.85) | (3.67) | 0.30 | (0.76) | (0.23) | (0.08) |
Earnings/Sh
|
|||
| — | — | — | 0.05 | (0.36) | (0.28) | (0.72) | 0.17 | 0.13 | 0.30 |
Cash Flow/Sh
|
|||
| — | — | — | (0.32) | (0.11) | (0.15) | (0.13) | (0.24) | (0.05) | (0.04) |
Capex/Sh
|
|||
| — | — | — | (0.27) | (0.47) | (0.43) | (0.85) | (0.07) | 0.08 | 0.26 |
Free CF/Sh
|
|||
| — | — | — | 0.00 | (0.87) | 2.96 | 1.13 | 0.45 | 0.42 | 0.48 |
Book Value/Sh
|
|||
| — | — | — | 32 | 34 | 102 | 148 | 132 | 124 | 126 |
Shares
|
|||
| — | — | — | 0.00 | 0.00 | 0.00 | 28.90 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | 0.00 | 0.00 | 9.49 | 3.72 | 1.02 | 0.59 | 0.58 |
PS Ratio
|
|||
| — | — | — | 16,325.50 | 130.07 | 8.16 | 8.14 | 6.85 | 3.80 | 2.88 |
PB Ratio
|
|||
| — | — | — | 0.00 | 0.00 | 8.84 | 4.19 | 1.58 | 1.15 | 1.02 |
EV/Sales
|
|||
| — | — | — | 0.00 | (75.84) | (52.28) | (12.22) | (64.29) | 41.12 | 9.51 |
EV/FCF
|
|||
| — | — | — | 2 | (12) | (28) | (107) | 22 | 16 | 37 |
Op' Cash Flow
|
|||
| — | — | — | (10) | (4) | (16) | (19) | (32) | (7) | (5) |
Capex
|
|||
| — | — | — | (9) | (16) | (44) | (125) | (10) | 9 | 32 |
FCF
|
|||
| — | — | — | — | 28 | 924 | 712 | 583 | 409 | 123 |
Working Cap'
|
|||
| — | — | — | — | 217 | 734 | 741 | 738 | 552 | 364 |
Total Debt
|
|||
| — | — | — | — | 207 | (168) | 173 | 215 | 182 | 132 |
Net Debt
|
|||
| — | — | — | 0 | (30) | 302 | 167 | 59 | 52 | 61 |
Sh' Equity
|
|||
| — | — | — | 0.00% | (26.19%) | (52.55%) | 3.98% | (10.36%) | (3.60%) | (1.61%) |
ROA
|
|||
| — | — | — | 0.00% | (6.06%) | (18.58%) | (4.75%) | (29.78%) | (18.11%) | (6.74%) |
ROIC
|
|||
| — | — | — | 0.00% | (21.45%) | (278.16%) | 18.84% | (88.42%) | (52.34%) | (16.87%) |
ROE
|
|||
SkinHealth Systems Inc. peers in Household & Personal Products
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| SLSN Solesence, Inc. | $57.2M | 0.0× | Compare |
| WALD Waldencast PLC | $134.7M | 0.0× | Compare |
| GROV Grove Collaborative Holdings, Inc. | $44.8M | 0.0× | Compare |
| YSG Yatsen Holding Limited Sponsored ADR | $158.2M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| UG United-Guardian, Inc. | $33.3M | 13.1× | Compare |
| DSY Big Tree Cloud Holdings Limited | $29.8M | 20.1× | Compare |
| NUS Nu Skin Enterprises, Inc. | $224.9M | 0.0× | Compare |
| ACU Acme United Corporation. | $242.7M | 24.4× | Compare |
SkinHealth Systems Inc. (SKIN) key facts
- SkinHealth Systems Inc. (SKIN) is a Household & Personal Products company in the Consumer Defensive sector, listed on Nasdaq.
- SkinHealth Systems Inc.’s revenue for fiscal 2025 (year ended December 2025) was $300.8 million, down 10.0% from fiscal 2024.
- SkinHealth Systems Inc. reported a net loss of $9.5 million, or a loss of $0.08 per share, for fiscal 2025.
- As of September 25, 2026, SKIN traded at $0.66, a market capitalization of $78.4 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 0.3× sales.
- Return on equity was −16.9% and debt-to-equity 6.21.
SkinHealth Systems Inc. (SKIN) Latest News
15 Sep
SkinHealth Systems Inc. unveils new Hydrafacial and HydraScalp with Keravive clinical data at the 2026 Science of Skin Summit. New clinical data presentation for product line at industry summit signals moderate advancements in offerings and positioning.
8 Sep
SkinHealth Systems Inc. launches two new Hydrafacial treatment enhancers to expand personalization options and improve treatment results. New treatment enhancers constitute significant product launches that strengthen core offerings.
26 Aug
SkinHealth Systems Inc. (SKIN) launches Hydrafacial Impact to enable providers to accelerate practice growth. Product launch represents major strategic move targeting provider expansion and revenue growth.
11 Aug
SKIN examines its international revenue performance and related metrics. International revenue exploration points to potential market expansion effects for SKIN.
7 Aug
The Beauty Health Company presented Q2 2026 earnings results and business updates during its earnings call. Q2 2026 earnings results and guidance directly shape near-term stock movement and investor outlook.
SkinHealth Systems Inc (SKIN) reported strong EBITDA beat in Q2 2026 earnings call. Strong EBITDA beat signals improved profitability likely to lift stock performance and investor sentiment.
SkinHealth Systems Inc. (SKIN) Q2 earnings call highlighted financial results, revenue trends, operational updates, and forward guidance. Earnings highlights deliver financial metrics that can shift short-term investor views without guaranteeing major strategic change.
6 Aug
SkinHealth Systems Inc. reported Q2 earnings with focus on key performance metrics. Q2 earnings and key metrics disclosure can substantially shift stock valuation and investor outlook.
SkinHealth Systems Inc. (SKIN) released its second quarter 2026 financial results. Quarterly earnings releases directly shape investor views and near-term stock movement.
SkinHealth Systems Inc. (SKIN) posted a Q2 loss and missed revenue estimates. Q2 loss and revenue shortfall indicate weaker results likely pressuring near-term valuation and sentiment.
30 Jul
SkinHealth Systems Inc. (SKIN) Q2 earnings are expected to decline. Anticipated Q2 earnings decline for SKIN signals negative financial trajectory likely to pressure stock valuation and investor outlook.
14 Jul
SkinHealth Systems Inc. (SKIN) upgraded to Strong Buy rating. Analyst upgrade to Strong Buy can moderately lift near-term investor sentiment and share price for SKIN.
7 Jul
SkinHealth Systems Inc. (SKIN) obtained new FDA clearance for SkinStylus® to improve periorbital wrinkles across all skin types. New FDA clearance expands SkinStylus® indications to all skin types and supports higher revenue potential.
7 Jun
SkinHealth Systems (SKIN) investment narrative shifts following revised guidance and fair value reset. Guidance revision and fair value reset directly alter SKIN valuation metrics and investor outlook.
2 Jun
Hydrafacial introduces HydraScalp® with Keravive™ as next evolution in scalp health treatments. New product launch expands core offerings and targets scalp health market growth.
12 May
SkinHealth Systems Inc. (SKIN) international revenue trends show strong growth potential, signaling expanded global market opportunities and warranting close investor attention. SKIN's international revenue trends signal moderately noticeable growth in key financial areas without fundamentally altering long-term trajectory.
8 May
Beauty Health (SKIN) Q1 earnings call highlights key financial results, operational updates, and forward guidance. Q1 earnings call highlights disclose financial performance, strategic initiatives, and outlook that significantly influence SKIN's stock price and investor sentiment.
SkinHealth Systems Inc. (SKIN) released Q1 2026 earnings call summary covering financial results and outlook. Quarterly earnings updates provide financial metrics that can shift short-term investor sentiment and valuation.
7 May
SkinHealth Systems Inc. (SKIN) Q1 earnings compared to analyst estimates, with analysis of key metrics. Q1 earnings versus estimates directly affect financial performance and investor sentiment.
SkinHealth Systems Inc. (SKIN) reported a first-quarter loss and revenue below analyst estimates. Q1 loss and revenue miss highlight financial weakness with moderate impact on investor sentiment and near-term performance.
SkinHealth Systems Inc. (SKIN) reported first quarter 2026 financial results. Quarterly earnings reports moderately influence financial performance and market sentiment.
22 Apr
The Beauty Health Company (SKIN) announces corporate rebrand to SkinHealth Systems, reflecting its evolution into a clinically driven, science-backed medical aesthetics platform. Rebrand to SkinHealth Systems marks a major strategic shift toward clinical medical aesthetics, poised to significantly influence competitive positioning and investor sentiment.
25 Mar
Analysts are reworking price targets and FY26 EBITDA expectations for The Beauty Health Company (SKIN), signaling a shift in its investment narrative. Analyst revisions to price targets and FY26 EBITDA expectations signal significant shifts in investor sentiment and SKIN's future trajectory.
17 Mar
Beauty Health (SKIN) international revenue trends merit close attention when evaluating the stock, as they signal key growth dynamics often underappreciated by investors. International revenue trends directly affect SKIN's financial performance and investor sentiment without fundamentally altering long-term trajectory.
13 Mar
The Beauty Health Company (SKIN) released Q4 2025 earnings call summary detailing financial results, operational updates, and forward guidance. Q4 2025 earnings call summary provides critical financial metrics, strategic insights, and guidance directly influencing SKIN's market performance and investor outlook.
12 Mar
The Beauty Health Company (SKIN) released Q4 earnings call highlights detailing financial performance, operational updates, and forward guidance. Q4 earnings call highlights reveal key financial results and strategic outlook directly impacting SKIN's valuation and investor confidence.
The Beauty Health Company (SKIN) released its Q4 2025 earnings call transcript, covering financial results, operational highlights, strategic updates, and forward guidance. Q4 2025 earnings transcript discloses financial performance, guidance, and strategic shifts that significantly affect investor sentiment and market trajectory.
Beauty Health (SKIN) Q4 earnings key metrics compared to estimates, highlighting performance against expectations. Q4 earnings metrics versus estimates significantly impact SKIN's financial trajectory and investor sentiment.
The Beauty Health Co (SKIN) Q4 2025 earnings call highlights navigating revenue challenges. Revenue challenges in Q4 2025 earnings call moderately affect SKIN's financial performance and market sentiment.
The Beauty Health Company (SKIN) reported a Q4 net loss but exceeded revenue estimates. Q4 loss despite revenue beat indicates mixed financial results with moderate effects on near-term performance and sentiment.